Aims 5-Aminoimidazole-4-carboxamide riboside (AICAR) is an endogenous activator of AMPK, a central regulator of energy homeostasis. Loss and/or reduction of AMPK signaling plays an important role in the development of insulin resistance in type 2 diabetes. The loss of AMPK in diabetes could be due to a loss of AICAR. The aim of this study was to characterize urine levels of AICAR in diabetes and determine whether an association exists with respect to late complications, e.g., retinopathy, nephropathy and neuropathy. Methods Urine AICAR was measured by liquid chromatography tandem mass spectrometry in 223 patients consisting of 5 healthy controls, 63 patients with pre-diabetes, 29 patients with newly diagnosed type 2 diabetes and 126 patients with long-standing type 2 diabetes. For statistical analyses, nonparametric Kruskal-Wallis test, one-way ANOVA and multivariate regression analysis were performed to investigate the associations of urinary AICAR excretion within different groups and different clinical parameters. Results The mean urine AICAR for all 223 patients was 694.7 ± 641.1 ng/ml. There was no significant difference in urine AICAR between the control and patients with diabetes (592.3 ± 345.1 vs. 697.1 ± 646.5 ng/ml). No association between any of the biochemical and/or clinical parameters measured and urine AICAR was found, with the exception of age of patient (R = − 0.34; p < 0.01) and estimated glomerular filtration rate (R = 0.19; p = 0.039). These results were confirmed additionally by linear regression analysis. Conclusions Clinical diabetes is not associated with a change in endogenous AICAR levels. Loss of AICAR may therefore not be a mechanism by which AMPK signaling is reduced in diabetes.
NSS
Neuropathy symptom score (NSS) NDS Neuropathy disability score (NDS) RAAS Renin-angiotensin-aldosterone system Background AMP-activated protein kinase (AMPK) is an evolutionary conserved serine/threonine kinase that functions as a master regulator of energy homeostasis [1] . Upon activation, AMPK signals through its downstream substrates to restore normal energy levels by stimulating metabolic processes that generate ATP, such as fatty acid oxidation, or by inhibiting those that use ATP, such as triglyceride and protein synthesis [2] . Regulation of AMPK is of great interest in the study of diabetes and metabolic syndrome as evidence would suggest that loss and/or reduction of AMPK signaling plays an important role in the development of insulin resistance. It has been reported in multiple animal models with a metabolic syndrome that there is decreased AMPK activity in the muscle [2] and that pharmacological activation can prevent and/or ameliorate the pathologies of diabetes [2] . Evidence also exists that AMPK activity is reduced in skeletal muscle and adipose tissues of humans with either type 2 diabetes or obesity [3, 4] .
5-Aminoimidazole-4-carboxamide riboside (AICAR) is an endogenous activator of AMPK [5, 6] . It is an intermediate produced during de novo purine biosynthesis and an analog of adenosine monophosphate (AMP). It can be phosphorylated by adenosine kinase to become ZMP which can bind to the cystathionine beta-synthase (CBS) domains of AMPK's γ-subunit leading to an allosteric change [5] . This change makes AMPK a better substrate for its upstream kinases to phosphorylate it at Thr172 and inhibits dephosphorylation at this site by the protein phosphatases, PP2A and PP2C [7, 8] . This combined effect significantly increases the activity of AMPK ex vivo [9] . Treatment with AICAR has been shown to prevent and/or reverse metabolic syndrome in animal models. In ob/ob mice, fa/fa rats, as well as rats fed on a high-fat diet, AICAR treatment has been shown to improve glucose tolerance, whole-body glucose disposal, as well as reduce hepatic glucose output and plasma triglycerides and free fatty acid levels [10] [11] [12] [13] . AICAR has also been shown to increase expression of genes involved in oxidative metabolism in muscle [14, 15] . Untrained mice that were treated with AICAR (500 mg kg ) over four weeks significantly improved their running endurance in a treadmill experiment by 44% [16] . Due to its performanceenhancing effects, AICAR has been prohibited for use in athletes by the World Anti-Doping Agency (WADA) since 2009 [17] .
Renal clearance of endogenously produced AICAR has been described. In a cohort of nondoping athletes, the mean urinary concentration of AICAR, as determined by isotope dilution, liquid chromatography, tandem mass spectrometry, was 2186 ± 1655 ng/ml. The concentration was found to differ depending on gender, with females having significantly lower levels [18] . Based upon these measurements, it was concluded that AICAR concentrations > 20 µg/ml would be considered inconsistent with an endogenous production in healthy individuals. Elevated amounts of eliminated AICAR are known to associate with vitamin B12 and folic acid deficiencies, due to an impaired AICAR transformylase activity [19] as well as in leukemia patients and patients with hypoxanthine-guanine phosphoribosyl transferase deficiency [20] [21] [22] . To our knowledge, there is nothing known about the impact of other physiological parameters like nutritional purine intake or a seasonal or diurnal variation, although AMPK was shown to be involved in circadian regulation [23] .
Urine was selected in this study over red blood cell measurement as it is not only well established [24] but also could be performed within our routine screening panel for inborn errors of purine and pyrimidine biosynthesis (DietmarHopp-Metabolic Centre, quality assured for clinical use via the ERNDIM scheme [25] ). Measurement in red blood cells is a better indicator of long-term levels [26] , but this was not considered superior as a steady state was expected in the patients.
Within the context of diabetes, renal output of AICAR remains unknown. However, as the activity of AMPK has been reported to be decreased in diabetes and AICAR is a potent endogenous activator of AMPK, the loss of AICAR by an increased renal output may provide a noninvasive means for assessing those patients which are at risk of developing diabetes as well as at risk of developing late complications. The aim of this study was to characterize the urinary levels of AICAR in a cohort of healthy controls and patients with pre-diabetes, as well as patients with newly diagnosed and long-term type 2 diabetes, and determine whether an association exists with classical markers of diabetology, markers of metabolic stress and late diabetic complications.
Methods

Patient cohorts
Patients with pre-diabetes and healthy controls were recruited from the Pre-diabetes Lifestyle Intervention Study (PLIS, multicenter study, local ethics number S-245/2013). Newly diagnosed patients with diabetes mellitus type 2 were recruited from the German Diabetes Study (DDS, multicenter study, local ethics number S-232-2013), and patients with long-standing type 2 diabetes mellitus were recruited from Heidelberg Study on Diabetes and Complications
3
(HEIST-DiC, local ethics number S-383/2016). Informed consent was obtained from all individual participants included in the study, and blood and spot urine samples were obtained under fasting conditions in all three studies. Following collection, urine was centrifuged (2000 rpm; 5 min; 4 °C) and ca.1 ml aliquots were frozen at − 80 °C. Preanalytical degradation was very unlikely to occur as a robust stability of AICAR was described at room temperature even in red blood cells for at least 5 days before [26] . All procedures were approved by the local ethics committee of the University of Heidelberg. The characteristics of the different patient cohorts studied are given in Table 1 .
Assessment of clinical parameters and late diabetic complications
Standard laboratory parameters were assessed in the central laboratory of the Heidelberg University Hospital. The patients were starving 10 h before taking blood and urine samples. The glomerular filtration rate was estimated by using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [27] . Blood pressure and heart rate were measured on the left upper arm in a resting state after 5 min, while patients were sitting, using OMRON M8RC IntelliSense Dual Check System. Weight measured using TANITA BWB-620A scale. Height was measured using Längenmesstechnik GmbH Limbach-O System Dr. Keller I. All devices are calibrated on a regular basis by our clinical technicians. Retinopathy was assessed by central 1-field fundus photography (NIDEK AFC-230, NIDEK CO LTD, Padua, Italy; Canon EOS 5D Mark II, Canon Deutschland, Krefeld, Germany). Study participants were screened for neuropathy by using neuropathy symptom score (NSS) [28, 29] and neuropathy disability score (NDS) [30] . Skin auto-fluorescence, which partially reflects the accumulation of AGEs in the skin, was determined by the use of noninvasive fluorescence-based measurement (DiagnOptics AGE Reader SU, DiagnOptics 
Measurement of urinary AICAR by liquid chromatography tandem mass spectrometry
Urine samples were diluted to 1 mmol/L creatinine with aqua dest. prior analysis. Creatinine determination in urine was performed on an Olympus AU 480 analyzer using the creatinine kit (Beckman Coulter, Krefeld, Germany). This test is based on the alkaline-creatinine-picrate method [31] . Then, 20 µl of 50 µM thymine-d4 internal standard (Cambridge Isotopes, Tewksbury, MA, USA) was added to a 180-µl aliquot of diluted urine and was filtrated with a centrifuge filter (Merck Millipore, Darmstadt, Germany) and a pore size of 0.1 µm. Analysis was performed on a HPLC system coupled to a Quattro Ultima triple quadrupole mass spectrometer (Micromass, Manchester, UK) equipped with an electrospray ion source and a Micromass MassLynx data system according to Hartmann et al. [25] with minor modifications. In brief, optimized multiple reaction monitoring (MRM) experiment was performed on the most abundant ion transition (m/z 259-127), which was identified by the direct infusion of AICAR (Sigma-Aldrich, Darmstadt, Germany). Collision gas was argon with collision energy of 14 eV. The mass spectrometer was operated in positive ion mode with a needle voltage of 3.15 kV. The system was equipped with a Phenomenex Aqua C18 column (2.0 × 250 mm, 5 µm particle size, Aschaffenburg, Germany) preceded by a C18 2.0 × 4 mm pre-column cartridge (Phenomenex, Aschaffenburg, Germany 
Results
For the total study cohort of 223 patients (Table 1) , regardless of patient classification, the mean urine AICAR was determined to be 694.7 ± 641.1 ng/ml (Fig. 1a) . There was no significant difference in urine AICAR between the controls and patients with diabetes (592.3 ± 345.1 vs. 697.1 ± 646.5 ng/ml; nonparametric Kruskal-Wallis test, Fig. 1b ). Subgroup analysis with respect to the patients with diabetes showed a trend with patients with a pre-diabetes and those with newly diagnosed type 2 diabetes having a 1.3-fold and 1.6-fold increase, respectively, in urine AICAR as compared to the control group; however, these differences were nonsignificant (nonparametric Kruskal-Wallis test, Fig. 1c) (Fig. 1c) . The analysis in different age groups showed that the younger subjects < 39 years (n = 11) had significantly higher urinary AICAR excretion compared to the rest of the participants (F = 3.4; p < 0.01). Similar results were shown with the Kruskal-Wallis test (χ 2 = 16.0; p < 0.01). Normalization to the urine creatinine did not affect the relative differences observed between the different groups ( Supplementary  Figure 1) .
Correlation analysis for the total study cohort showed no association between any of the biochemical and/or clinical parameters measured and urine AICAR. There was no association with skin advanced glycation end products (AGEs), a noninvasive marker for post-translational modifications (data not shown). There was also no association of urine AICAR with symptoms of retinopathy or neuropathy (data not shown). Multivariate regression analysis for the panel data with urine AICAR, as the dependent variable, confirmed this lack of association with exception for age and eGFR ( Table 2 ). All joint effects of the parameters measured were found to be nonsignificant. The only exceptions were with respect to the age of the patients, which correlated negatively (R = − 0.34; p < 0.0001; Fig. 2a) , and glomerular 
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filtration, which correlated positively (R = 0.19; p = 0.039; Fig. 2b ). Despite these significant correlations, analysis of either age or glomerular filtration with respect to the diabetes subgroups showed that the differences observed in urine AICAR could not be directly explained by either of these variables (data not shown). Normalization to the urine creatinine did not affect the correlation or multivariate analysis (data not shown).
Discussion
In this study, it was found that urine AICAR was unchanged in patients with diabetes as compared to healthy controls, and while there was a tendency of patients with pre-diabetes and with newly diagnosed type 2 diabetes to having progressively higher urine AICAR, as compared to control patients, these differences were found to be nonsignificant. It remains speculative if further studies with larger patient cohorts might reveal a significant change, and if this then might be physiologically relevant. A limitation of our pilot study is that an a priori power calculation was not possible, as no comparable studies on diabetic patients have been published so far. Moreover, the small number of healthy controls is a major limitation of our study. Nevertheless, the values are consistent with the published data [18] , and it is unlikely that an increase in the numbers would substantially change the outcome of this study. A significant decrease in urine AICAR was observed between patients with newly diagnosed type 2 diabetes and those with a long-standing type 2 diabetes. This patient group is well controlled with respect to their hyperglycemia and can therefore be considered as a representative of a "healthy" population with diabetes. The significant reduction in urine AICAR within this group could therefore be reflective of the good management of their condition. However, further analysis would be required to validate this and whether the observed trends are indeed a reflection of the diabetes status.
It was surprising to find that urine AICAR did not correlate with any of the standard biochemical and/or clinical parameters used in assessing diabetes and its associated complications, such as fasting glucose, HbA1c or BMI, suggesting that AICAR does not necessarily play a role in diabetes and the development of its complications. As the patient's diet was not assessed, we cannot evaluate its influence on the urine AICAR levels. Analysis of the entire study cohort showed that urine AICAR significantly correlated with the age of the patients and glomerular filtration. These positive and negative associations, respectively, could not, however, explain the observed differences in urine AICAR within the subgroups of patients with diabetes. It has previously been reported that age is associated with a decline in renal function [32] , and within the current study cohort, a significant negative correlation between glomerular filtration and patient age, regardless of diabetes, was observed (R = − 0.3585; p < 0.0001; Fig. 1c ). The decrease in urine AICAR with age may therefore only be a reflection of physiological reduction in glomerular filtration and not as a consequence of diabetes. Further patient cohorts are therefore required which include patients with diabetes with severely impaired renal function.
Overall, the mean urine AICAR level for the entire study cohort was found to be 694.7 ± 641.1 ng/ml, with control patients having a mean level of 592.3 ± 345.1 ng/ ml. This amount of urine AICAR is approx. threefold lower than has been previously reported for healthy patients [18] . The differences observed could be explained by ages of the respective study cohorts. In the study by Thomas et al. [33] , the urine AICAR was measured in elite athletes and while the age of the subjects is not stated, it can be assumed that the age demographic for the cohort ranged between 20 and 30 years. In the current study, the mean age of the entire study cohort was 58.91 ± 10.41 years. It can therefore be hypothesized that the lower levels of urine AICAR are due to age-dependent decrease in glomerular filtration. Future studies should therefore include patients Univariate Spearman's rank correlation coefficient (R) was used for correlation analysis. Values of p < 0.05 were considered statistically significant of different ages, particularly with respect to the control group, as to further assess whether this variable affects urine AICAR.
Conclusions
The lack of any significant differences in urine AICAR would suggest that changes in AICAR do not underlie the loss in AMPK activity in diabetes. However, to substantiate this, a measure of AMPK activity, such as within the peripheral blood mononuclear cells, would be required. Although endogenous AICAR may not be changed in diabetes, exogenous supplementation with AICAR has been shown to be an effective means for inducting AMPK [10] [11] [12] [13] . It is unlikely that AICAR will be used as treatment option in diabetes due to its poor bioavailability and a short half-life [34] and its nonspecific effects, such as the inhibition of fructose-1,6-bisphosphatase [35] and stimulation of muscle glycogen phosphorylase [36] . However, the use of AMP analogs as well as activators of AICAR/ AITC metabolism may provide a more potent and specific means for inducing AMPK in the future [37] .
